

Ultrafiltration

Transvivo, which has developed the world's first *in vivo* plasma filtration catheter for blood purification, will be presenting at the upcoming, groundbreaking 'in circulation' conference.

by Ronald C. Trahan

TRANSVIVO has developed the world's first *in vivo* plasma filtration catheter for blood purification. The catheter and fluid-control module combine to form the first *Slow Continuous Intracorporeal Plasmapheresis* (SCIP™) system, with applications for a large number and variety of blood disorders. Transvivo has begun clinical trials using the SCIP system to treat fluid overload in CHF patients. This *in vivo* system was touted as "revolutionary" during the recent American Society for Apheresis & World Apheresis Association Joint Convention. The Company's mission is to create a unique platform for continuous, hemodynamic management of vascular, kidney, liver, and other organ disorders *in vivo*. Transvivo has created a novel platform technology that promises to support existing therapeutic regimens by eliminating blood cells from external blood-purification circuits.



Dr. Hal Handley, Jr.
EVP and CSO of Transvivo, Inc., was a co-founder and inventor on the founding patents for IDEC Pharmaceuticals, now IDEC-Biogen.

This may ultimately allow for the creation of a 'wearable' artificial kidney. The technology has innumerable applications—for example, congestive heart failure, kidney disease, autoimmune diseases, organ failure, trauma, sepsis and tissue bio-engineering. The Transvivo SCIP™ system provides several days of uninterrupted therapy at hemodynamically tolerable and continuous rates. In contrast, established technology requires frequent interruptions of therapy to replace lines and cartridges due to blood clotting. The SCIP™ system eliminates these interruptions by eliminating the clotting cells, allowing the gentle processing of plasma from patients suffering from CHF or traumatic overhydration or from those requiring plasma exchange or toxin removal. The device is expected to diminish the current costs associated with long-term or repetitive patient care. The Company, which is headquartered in Napa, Calif., has built a strong proprietary platform of 18 issued or allowed patents, as well as numerous patents pending, that describe the design and filtration devices for therapeutic apheresis, acute fluid overload, trauma, kidney disease, diabetes, segmental edema, *in vivo* ultrafiltration, dialysis and other comparable improvements to continuous renal replacement therapies.

"We are seeking to develop early strategic relationships with well positioned companies in marketing and distribution," says Harold H. Handley, Jr. Ph.D., EVP and CSO for Transvivo. "We are excited at the prospect of presenting our story at this unique 'in circulation' investor conference and meeting the many multinational medtech companies known to go fishing in the Medtech Insight waters."

'in circulation' will be a single-track format consisting of 10-minute company presentations immediately followed by individual meetings in private breakout rooms. The conference will also feature an interactive physician panel and a product exhibition/networking dinner. More event details will be posted regularly at <http://www.medtechinsight.com/incirc-01.html>. □

**In Circulation: Strategic Partnering and Investing in Circulatory Medicine
The Hyatt Regency-McCormick Place, Chicago, Illinois, April 27, 2005**

This is the first 'specialty-specific' investment conference focusing on early-stage companies developing products for both diagnosis and treatment of diseases associated with the circulatory system. This meeting will feature more than 30 companies developing technologies for such high-growth segments as interventional cardiology, stroke, cardiovascular diagnostics and more.

To register for this conference, please call 949-219-0150 or 888-290-2225 (toll-free in the U.S.), send an email to sales@medtechinsight.com, or **register online at www.medtechinsight.com.**

What leading investors are saying about their participation at MedTech Insight's *In³* and specialty investor conferences:



"I have found that Medtech Insight's conferences are packed with some very interesting emerging companies, who get the opportunity to be courted one-on-one by some of the biggest compa-

nies in the medtech industry. If you're an emerging company looking to partner with an established company, Medtech Insight's meetings are certainly the place to be."

John H. Icardi
Partner

Strategic Business Works
Cary, North Carolina



"Medtech Insight conferences are a wonderful source of potential winners in leading-edge medical technologies. I imagine these conferences are

always well-attended because insiders knows it is a superb venue in which to inspect many novel investment opportunities at one time."

Hideki Mitani
Managing Director
Roberts Mitani LLC



"Medtech Insight's conferences provide me with a great opportunity to gain exposure in a relatively short period of time to interesting investment opportunities and to connect with others in the industry to discuss developing issues in the medical device industry."

Adele Cirone Oliva
Healthcare Investor
Apax Partners

Ronald C. Trahan is President/CEO of Ronald Trahan Associates Inc. (www.ronaldtrahan.com), a public relations/investor relations firm that serves big and small companies, both public and private.